Patentscope RSS feed

Forms of lumacaftor and processes for the preparation thereof (Thu, 21 Feb 2019)
The present disclosure provides amorphous lumacaftor, amorphous solid dispersions of lumacaftor, crystalline lumacaftor acetic acid solvate, crystalline lumacaftor ethyl acetate solvate, and processes for the preparation thereof. The lumacaftor forms disclosed herein may be useful for the preparation of oral dosage forms for treating cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases.
>> Read More

NOVEL FORMS OF LUMACAFTOR AND PROCESSES FOR THE PREPARATION THEREOF (Thu, 06 Apr 2017)
The present disclosure provides amorphous lumacaftor, amorphous solid dispersions of lumacaftor, crystalline lumacaftor acetic acid solvate, crystalline lumacaftor ethyl acetate solvate, and processes for the preparation thereof. The lumacaftor forms disclosed herein may be useful for the preparation of oral dosage forms for treating cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases.
>> Read More

Novel dipeptidyl peptidase IV inhibitors and processes for their preparation and pharmaceutical compositions containing them (Fri, 27 May 2011)
Patent 571319 Disclosed is a compound of formula I, where Y is CN, n is 1 or 2, and wherein the other substituents are as defined in the specification. Also disclosed is a process for the synthesis of the compound. Also disclosed is the use of the compound to treat diabetes, a diabetic complication such as coronary artery disease, stroke, hypertension, nephropathy, peripheral vascular disease, neuropathy, and retinopathy, a metabolic disorder, impaired glucose tolerance, impaired fasting glucose, a diabetic complication, dislipidemia, hypercholesteromia, hypolipidemia, obesity, hyperglycemia, or for lowering blood glucose.
>> Read More

DIBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 (Fri, 30 Mar 2012)
Patent 575389 Disclosed are compounds of formula (I) or any tautomer, stereoisomer, enantiomer, diastereomer, polymorph, pharmaceutically acceptable salt, pharmaceutically acceptable hydrate, pharmaceutically acceptable solvate, or N-oxide thereof, and methods for their preparation. Specific examples of a compound of formula (I) include: 1-(4-Methoxydibenzo[b,d]furan-1-yl)-4-oxocyclohexanecarbonitrile, Ethyl 6-cyano-6-(4-methoxydibenzo[b,d]furan-1-yl)-2-methyl-5,6,7,8-tetrahydroquinoline-3-carboxylate, and Ethyl {[6-cyano-6-(4-methoxydibenzo[b,d]furan-1-yl)-2-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]oxy}acetate. Also disclosed are the use of compounds of formula (I) in treating allergic inflammatory conditions such as bronchial asthma, nephritis and allergic rhinitis, and more broadly, for treating asthma, chronic obstructive pulmonary disorder (COPD), allergic rhinitis, allergic conjunctivitis, respiratory distress syndrome, chronic bronchitis, nephritis, rheumatoid spondylitis, osteoarthritis, atopic dermatitis, eosinophilic granuloma, psoriasis, rheumatoid septic shock, ulcerative colitis, multiple sclerosis, chronic inflammation, Crohn���s syndrome and a central nervous system (CNS) disorder...
>> Read More

Preparation of cobicistat intermediates (Thu, 13 Oct 2016)
The present disclosure provides crystalline piperidine sulfamoyl intermediates of formula 8 and 9. The present disclosure also relates to an improved process for the preparation of cobicistat using compounds of formulae 8 and 9. embedded image
>> Read More

Process for the preparation of empagliflozin (Thu, 03 Nov 2016)
An improved process for the preparation of empagliflozin is disclosed. Novel intermediates of formulas (13) and (14) for the preparation of empagliflozin are also disclosed, wherein R1 and R2 are independently hydrogen or hydroxyl protecting groups. embedded image
>> Read More

Process for the preparation of sofosbuvir (Thu, 03 Nov 2016)
The present disclosure relates to processes for the preparation of sofosbuvir or of its pharmaceutically acceptable salts. The present disclosure also provides intermediates useful in the synthesis of sofosbuvir.
>> Read More

PREPARATION OF COBICISTAT INTERMEDIATES (Wed, 12 Oct 2016)
The present disclosure provides crystalline piperidine sulfamoyl intermediates of formula 8 and 9. The present disclosure also relates to an improved process for the preparation of cobicistat using compounds of formulae 8 and 9.
>> Read More

PREPARATION OF COBICISTAT INTERMEDIATES (Thu, 11 Jun 2015)
The present disclosure provides crystalline piperidine sulfamoyl intermediates of formula 8 and 9. The present disclosure also relates to an improved process for the preparation of cobicistat using compounds of formulae 8 and 9.
>> Read More

Diebenzofuran derivatives as inhibitors of PDE-4 and PDE-10 (Thu, 12 Nov 2009)
The present invention relates to novel heterocyclic compounds that are useful as phosphodiesterase inhibitors (PDEs) in particular phosphodiesterase type 4 (PDE IV) inhibitors and phosphodiesterase type 10 (PDE 10) inhibitors, processes for their preparation, pharmaceutical compositions containing them and their use in treating allergic and inflammatory diseases as well as for inhibiting the production of Tumor Necrosis Factor (TNF-α). embedded image
>> Read More

Dibenzofuran derivatives as inhibitors of PDE-4 and PDE-10 (Thu, 02 Apr 2009)
The present invention relates to novel heterocyclic compounds that are useful as phosphodiesterase inhibitors (PDEs) in particular phosphodiesterase type 4 (PDE IV) inhibitors and phosphodiesterase type 10 (PDE 10) inhibitors, processes for their preparation, pharmaceutical compositions containing them and their use in treating allergic and inflammatory diseases as well as for inhibiting the production of Tumor Necrosis Factor(TNF-α).
>> Read More

DIBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 (Thu, 24 Dec 2009)

>> Read More

PROCESS FOR PREPARATION OF ALOGLIPTIN (Thu, 25 Jun 2015)
Processes for the preparation of alogliptin benzoate are disclosed. The present disclosure also provides intermediates useful in the synthesis of alogliptin benzoate.
>> Read More

Crystalline Darunavir (Thu, 27 Nov 2014)
The present invention relates to a non-solvated crystalline Darunavir, process for its preparation and pharmaceutical composition comprising it. The present invention also relates to a process for the preparation of amorphous Darunavir from a non-solvated crystalline Darunavir.
>> Read More

POLYMORPHIC FORMS OF BARICITINIB (Thu, 03 Jan 2019)
The present disclosure provides crystalline forms of baricitinib (formula (I)), crystalline forms of solvates of baricitinib and processes for the preparation thereof.
>> Read More

POLYMORPHS OF IXAZOMIB CITRATE AND PROCESSES FOR THE PREPARATION THEREOF (Thu, 23 Mar 2017)
The present disclosure provides amorphous ixazomib citrate and processes for the preparation thereof. Crystalline form Ml, form M2, form M3, and form M4 of ixazomib citrate are also disclosed. The present disclosure also encompasses processes for the preparation of those crystalline forms.
>> Read More

Amorphous Ixazomib Citrate (Thu, 04 Oct 2018)
The present disclosure provides amorphous ixazomib citrate and processes for the preparation thereof. Crystalline form M1, form M2, form M3, and form M4 of ixazomib citrate are also disclosed. The present disclosure also encompasses processes for the preparation of those crystalline forms.
>> Read More

PROCESS FOR THE PREPARATION OF SOTAGLIFLOZIN (Fri, 06 Sep 2019)
Sotagliflozin may be prepared using schemes and intermediates disclosed herein. Sotagliflozin may be incorporated into pharmaceutical dosage forms for treatment of diabetes.
>> Read More

TRAMADOL HBR-CELECOXIB CO-CRYSTAL (Thu, 27 Feb 2020)
The present invention provides a novel 1:1 co-crystal of (rac)-tramadol hydrobromide-celecoxib and processes for the preparation of the same by reacting (rac)-tramadol with hydrobromic acid and celecoxib. It also provides crystalline form of (rac)-tramadol hydrobromide.
>> Read More

PROCESS FOR THE PREPARATION OF VELPATASVIR (Thu, 13 Apr 2017)
The present disclosure provides a process for the preparation of velpatasvir intermediates of formula 5. The intermediates may be further converted to velpatasvir or pharmaceutically acceptable salts thereof.
>> Read More